Press Releases
[Basel, Switzerland , Tokyo, Japan-10 September 2015]
Drugs for Neglected Diseases initiative and Eisai Co., Ltd. to Test Drug Candidate for Eumycetoma
Patients suffering from virtually no R&D for this neglected disease
The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai’s anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world’s most neglected diseases.
[日本語][العَرَبِية]
More
[Basel, Switzerland – 7 September 2015]
Pivotal Clinical Trial to Begin for First Oral Drug Candidate Specifically Developed for Sleeping Sickness
Phase I study shows favourable safety profile and can be tested in patients
The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health (ECTMIH) in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.
More
[Basel, Switzerland – 7 September 2015]
Drugs for Neglected Diseases initiative Unveils New Plan for Neglected Patients
Aims to Deliver 16-18 Treatments for Up to 10 Diseases with EUR 650 Million
After having built the world’s largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating various operating models to better respond to the needs of patients, notably in low- and middle-income countries. The plan also paves the way for new diseases to be taken up in DNDi’s portfolio.
[English][Español][Français][Português]
More
